Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S
Tirzepatide: Tirzepatide, a dual GIP/GLP-1 agonist, represents a newer generation of metabolic peptides with potent weight loss effects through combined appetite suppression and metabolic enhancement
You should limit certain activities, such as strenuous exercise and any unnecessary touching of your face for two weeks after your procedure to allow your fat to settle into its new home and establish a healthy blood supply
The reason for the higher prevalence in this patient population is not clear, but could arise from the fact that the patients were selected for the presence of neuropathic symptoms that involved the feet, which could contribute to a poor performance on a walk test due to sensory deficits and pain
A handful of peptides carry full FDA approval for specific uses, including the GLP-1 medications semaglutide and tirzepatide for weight and metabolic health, and tesamorelin
